: iStockAnalyst.com Symbols Feed

Biostar Raises $3.6 Million

Fri, 06 Nov 2009 17:26:18 GMT

Biostar Pharmaceuticals has completed a private placement that raised $3.6 million in new capital. Biostar will use the proceeds to complete its new raw materials processing facility. By taking its raw material production in house, Biostar will lower costs and ensure its product quality. Biostar plans to sell excess raw materials to other pharmaceutical companies in the Shaanxi province.[More...]

Bulls Back On Track?

Fri, 06 Nov 2009 16:21:18 GMT

Good morning. With chants of "Dow 10K… Dow 10K" once again rising from the streets at the corner of Broad and Wall yesterday, it is easy to believe that the bulls are back on track and that we'll soon be looking at new highs for the stock market. And when reviewing the data inputs to yesterday's 204 point romp, it is also easy to don the Dow10K hat once again and join in on the celebration.[More...]

Ford's Main Problem: The UAW's Crippling Job Classifications And Work Rules

Fri, 06 Nov 2009 13:52:50 GMT

Ford's 2,215 page 2007 master contract with the UAW 1941 UAW-Ford contract[More...]

Options Intellignece Report : Options Activity for XRT, CVS, STT, PFE, FSYS & AEO

Thu, 05 Nov 2009 19:12:19 GMT

Today's tickers: XRT, CVS, STT, PFE, CVS, FSYS & AEO[More...]

Your Kind of Day?

Thu, 05 Nov 2009 19:06:48 GMT

As a rule, I try not to read too terribly much into a "Fed Day" as there is usually a big batch of volatility that may or may not mean much of anything come the dawn of the next day. Maybe, it's just me. Or maybe there are others that find themselves inclined to simply stand aside and watch the nuttiness from the sidelines on "Fed Days." But in any event, the volatility after a Fed announcement, while fun to watch, may not be telling as to what to expect in the future.[More...]

The Dollar-Proof Portfolio

Thu, 05 Nov 2009 17:31:14 GMT

Don't put off this important piece of the financial-planning process.[More...]

Celgene: Buy On A Pullback

Wed, 04 Nov 2009 17:04:19 GMT

“So why do we like Celgene so much, and how come we have time? The main reason I like it is its huge blood cancer drug Revlimid. $1.3 billion sales in 2008. It’s approved by the FDA to treat multiple myeloma. That’s a cancer of the plasma cells and bone marrow. These cancers are horrible…[More...]

What Investors Should Look for In Today’s Fed Statement

Wed, 04 Nov 2009 13:04:24 GMT

In its continuing efforts to nurture the fragile economic recovery, the U.S. Federal Reserve is widely expected to leave interest rates at record lows when it concludes its meeting today (Wednesday).[More...]

Are Discount Brokers Shares Worth Owning?

Wed, 04 Nov 2009 01:28:03 GMT

The third quarter was a favorable one for the longs. Except for a few short-lived, minor pullbacks stock prices moved higher through the quarter. Stock price volatility declined, takeover activity rose, and risk appetite improved to help the S&P gain 15%.[More...]

Technology Rises And Buying Facebook

Tue, 03 Nov 2009 16:54:11 GMT

Technology stocks have done well this year. The Technology Select Sector SPDR (XLK) bottomed out in March and by late October was up more than 60%. Tech has performed better than any other sector year-to-date – up 33.7% as of Friday’s close.[More...]

Business Highlights

Mon, 02 Nov 2009 22:47:00 GMT

3 strong economic reports lift recovery hopes
WASHINGTON (AP) - Hopes for the fledgling economic recovery got a boost Monday from better-than-expected news on manufacturing, construction and contracts to buy homes.
Construction spending rose a bigger-than-expected a 0.8 percent in September, while the National Association of Realtors said the volume of signed contracts to buy previously occupied homes rose 6.1 percent in September to a reading of 110.1.

: iStockAnalyst.com Symbols Feed

Biostar Raises $3.6 Million

Bulls Back On Track?

Ford's Main Problem: The UAW's Crippling Job Classifications And Work Rules

Options Intellignece Report : Options Activity for XRT, CVS, STT, PFE, FSYS & AEO

Your Kind of Day?

The Dollar-Proof Portfolio

Celgene: Buy On A Pullback

What Investors Should Look for In Today’s Fed Statement

Are Discount Brokers Shares Worth Owning?

Technology Rises And Buying Facebook

Business Highlights

Lazard: Wasserstein stock leads to $86.5M charge

Lazard: Wasserstein options lead to $86.5M charge

Unilab, Pfizer Figure in 'Drug War'

The Indianapolis Star Daniel Lee Column: Indiana Working to Create Its Own Identity With Investors

Eli Lilly to pay S. Carolina $45 million

Pfizer Sues Unilab Over Lipitor Drug

Lilly Q3 Net Income Up

Bristol-Myers posts higher 3Q sales, lower profit

Eli Lilly CEO banking on new drug pipeline

ConocoPhillips up 21% Since Added to Galtstock Long-Term Portfolio

MethylGene Reports Third Quarter 2009 Financial Results

Celldex Therapeutics Reports Third Quarter and Nine Month 2009 Financial Results

Myriad Genetics Reports First Quarter Fiscal 2010 Financial Results; Revenue Grows 22%; Net Income Rises 111% Compared to Prior Year

Nasdaq Panel Grants EpiCept's Request for Continued Listing

Phase Forward Reports Third Quarter 2009 Results

PicksThatMove.Com Announces Investment Opinion on TPS, ML, KOG, GAP and PFE

MichBio Expo &Amp; Conference Exhibitors Profiled

Ligand to Acquire Metabasis for Cash and Contingent Value Rights

Mission Bay Capital Announces First Venture Fund

Form 4 ALKERMES INC For: Nov 05 Filed by: BIBERSTEIN KATHRYN L (10K)

Form 4 WILSON LINDA S For: Nov 05 (10K)

Form 4 MYRIAD GENETICS INC For: Nov 05 Filed by: LANGER DENNIS (10K)

Form 4 MYRIAD GENETICS INC For: Nov 04 Filed by: SKOLNICK MARK H (10K)

Form 4 GILBERT WALTER PHD For: Nov 05 (10K)

Form 4 HENDERSON JOHN T For: Nov 05 (10K)

Form 4 MYRIAD GENETICS INC For: Nov 04 Filed by: Belle Gerald P. (10K)

Form 4 Redmond Cavan M. For: Oct 30 (10K)

Form 4 Dolsten Mikael For: Oct 30 (10K)

Form 4 SUSMAN SALLY For: Oct 30 (10K)